文献速递妇科肿瘤

免疫治疗与PARP抑制剂作为子宫内膜癌一线治疗:系统综述与网络Meta分析

Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis.
PubMed 文献 · Eur J Cancer · 2025-02-26

该系统综述与网络Meta分析纳入3210例子宫内膜癌患者,评估免疫检查点抑制剂(ICI)与PARP抑制剂(PARPi)联合铂类化疗的一线策略。在错配修复功能正常(MMRp)且p53异常患者中,PARPi联合ICI较ICI单药显著改善无进展生存(HR=0.47,95%CI 0.40-0.94);MMRd人群ICI单药疗效最佳,联合PARPi无额外获益。

要点

  • MMRp且p53异常患者中,PARPi联合ICI较ICI单药显著改善PFS(HR=0.47,95%CI 0.40-0.94)。
  • MMRd人群中ICI单药疗效最佳,联合PARPi未见额外获益。
  • PD-L1阳性(n=1121)可能预测ICI联合PARPi的更大获益。

核心结论

  • 在铂类化疗基础上联合ICI与PARPi,对p53异常的MMRp患者获益最大。
  • PD-L1是潜在有用的生物标志物,PD-L1阳性肿瘤更可能对ICI有反应。
  • 实施生物标志物检测对重新定义晚期或复发性子宫内膜癌的治疗范式至关重要。

研究设计与样本

  • 系统综述与网络Meta分析,采用频率学框架随机效应模型,并提取个体患者数据进行Meta分析。
  • 纳入评估ICI与PARPi一线治疗晚期或复发性子宫内膜癌的随机对照试验(RCT)。
  • 共纳入3210例子宫内膜癌患者。

主要发现

  • 在MMRp人群中,ICI联合PARPi较各单药未见统计学显著PFS获益。
  • 在MMRp且p53异常患者(n=590)中,PARPi联合ICI较ICI单药显著改善PFS(HR=0.47,95%CI 0.40-0.94),较PARPi单药有数值上更好的结局(HR=0.63,95%CI 0.26-1.57)。
  • 在p53野生型MMRp人群中,未观察到PARPi的获益。
  • PD-L1阳性(n=1121)似乎预测ICI联合PARPi的更大获益,联合治疗获益更大。
  • 在MMRd人群(n=769)中,ICI单药观察到最佳结局,PARPi无额外获益。

关键数值与推荐

  • 在MMRp且p53异常患者(n=590)中,PARPi联合ICI较ICI单药:HR=0.47(95%CI 0.40-0.94)。
  • 在MMRp且p53异常患者(n=590)中,PARPi联合ICI较PARPi单药:HR=0.63(95%CI 0.26-1.57)。
  • PD-L1阳性患者n=1121;MMRd人群n=769;联合治疗≥3级治疗相关不良事件发生率75.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several first-line therapeutic strategies have been evaluated alongside platinum-based chemotherapy in advanced or recurrent endometrial cancer (a/rEC). However, the optimal approach remains unclear. METHODS: A systematic review was conducted to identify randomized control trials (RCTs) that evaluate first-line therapeutic strategies in a/rEC involving immune checkpoint inhibitors (ICI) and PARP inhibitors (PARPi). A network meta-analysis with a frequentist framework using random-effects and an extracted individual patient data meta-analysis were performed. The primary endpoint was progression-free survival (PFS) by MMR status, p53 status within the MMRp population and PD-L1 status. RESULTS: A total of 3210 patients with EC were included. In the MMRp population, the combination (ICI and PARPi) showed a not statistically significant PFS benefit compared with each agent alone. In MMRp p53-abnormal patients (n = 590), combining PARPi and ICI statistically improved PFS compared to ICI alone (HR=0.47, 95 %CI 0.40-0.94) with a numerically better outcome compared to PARPi alone (HR=0.63, 95 %CI 0.26-1.57). No benefit from PARPi was observed in the p53 wild-type MMRp population. PD-L1-positivity (n = 1121) appears to predict more benefit from the addition of ICI and PARPi, with a larger benefit of combination therapy. In the MMRd population (n = 769), the best outcomes were observed with ICI alone, with no additional benefit of PARPi. Grade 3 or greater treatment-related adverse events were seen in 75.1 % patients treated with the combination. CONCLUSIONS: The addition of the combination of ICI and PARPi to platinum-based chemotherapy provides greatest benefit to p53-abnormal MMRp patients. PD-L1 is a potentially useful biomarker with PD-L1-positive tumors more likely to respond to ICI. Implementation of biomarkers is crucial to redefine the treatment paradigm in a/rEC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Villacampa G, Eminowicz G, Navarro V, et al. Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis. Eur J Cancer. 2025. PMID: 40031426. doi:10.1016/j.ejca.2025.115329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。